Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2026)
Indivior Pharmaceuticals (INDV) posted quarterly Long-Term Deferred Tax of $296.0 million for Q1 2026, up 6.09% year-over-year from $279.0 million in Q1 2025, and down 8.36% quarter-over-quarter from $323.0 million in Q4 2025.
Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $296.0 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax rose 6.09% year-over-year to $296.0 million; the TTM figure through Mar 2026 stood at $296.0 million (up 6.09% YoY), while the FY2025 annual figure was $323.0 million, up 16.61% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $296.0 million, down from $323.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $323.0 million in Q4 2025, with the low at $219.0 million in Q4 2022.
- The 5-year median for Long-Term Deferred Tax is $282.0 million (2025), against an average of $279.4 million.
- The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax jumped 108.57% in 2022, then declined 3.15% in 2024.
- Indivior Pharmaceuticals' Long-Term Deferred Tax stood at $219.0 million in 2022, then soared by 30.59% to $286.0 million in 2023, then declined by 3.15% to $277.0 million in 2024, then advanced by 16.61% to $323.0 million in 2025, then fell by 8.36% to $296.0 million in 2026.
- Business Quant data shows INDV's Long-Term Deferred Tax at $296.0 million in Q1 2026, $323.0 million in Q4 2025, and $285.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Indivior Pharmaceuticals | 4.54 Bn | 4.31 Bn | 294.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 271.00 Mn |
| Mar 31, 2026 | 296.00 Mn |
| Dec 31, 2025 | 323.00 Mn |
| Sep 30, 2025 | 285.00 Mn |
| Jun 30, 2025 | 270.00 Mn |
| Mar 31, 2025 | 279.00 Mn |
| Dec 31, 2024 | 277.00 Mn |
| Dec 31, 2023 | 286.00 Mn |
| Dec 31, 2022 | 219.00 Mn |
| Dec 31, 2021 | 105.00 Mn |